For patients with CRC, a randomized phase Ib/II trial299 concerning rilotumumab or ganitumab vs. panitumumab in patients with KRAS-wild-type metastatic CRC showed no significant benefit with the combined use of rilotumumab and panitumumab in terms of median OS (13.8 vs. 13.7 months, p = 0.71) in patients with MET-high disease compared with MET-low disease. The gene discussed is KRAS; the disease is colorectal carcinoma.